Preethi William, MD
Advanced Heart Failure and Transplant Cardiology · Mayfield Heights, OHNPI 1508177361
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $263 of the $425 with a category attached, or 61.9%. 9 manufacturers reported payments, led by Akcea Therapeutics, Inc. at 38.1% of the total. Reporting peaked in 2019 at $178 and has fallen 87.8% since, to $22 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in OH, where the typical reported total is $4,421.
Across 20 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akcea Therapeutics, Inc.$162
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$104
- Novartis$48
- Abbott$24
- Novo Nordisk$22
- Alnylam Pharmaceuticals Inc.$20
- plus $45 from 3 others
Across 11 payments — averaging $6956.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$44K
- AstraZeneca$32K
What the payments were for
- Food & beverage$26362%
- Education$16238%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akcea Therapeutics, Inc. | 3 | $162 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $104 |
| Novartis | 3 | $48 |
| Abbott | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Cvrx, Inc. | 1 | $13 |
How this compares
$425 in reported general payments places this provider in the 10th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 116 | $2,595,164 |
| VyndaqelTafamidis Meglumine | 17 | $364,472 |
| JardianceEmpagliflozin | 355 | $305,735 |
| EntrestoSacubitril/Valsartan | 293 | $233,653 |
| EliquisApixaban | 140 | $140,292 |
| FarxigaDapagliflozin Propanediol | 50 | $40,996 |
| XareltoRivaroxaban | 26 | $27,917 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $21,758 |
| Repatha SureclickEvolocumab | 19 | $16,329 |
| Metoprolol Succinate | 266 | $3,411 |
| Spironolactone | 410 | $2,717 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 128 | $1,803 |
| Torsemide | 105 | $1,765 |
| Potassium Chloride | 74 | $1,634 |
| Valsartan | 60 | $1,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $48 | $233,653293 claims |
| AstraZenecaFarxiga, Lokelma | $14 | $62,75478 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Mayfield Heights
- William AbrahamColumbus$802K
- Rami KahwashColumbus$379K
- Eugene ChungCincinnati$297K
- Kenneth VarianAkron$170K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Thomas O'BrienLiberty Township$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.